Roche unloads some rights to drug hopeful after asthma trial disappointment

ZURICH (Reuters) – Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments which could total more than $1 billion after the medicine produced only lacklustre results in an asthma study last year.

Powered by WPeMatico

Leave a Reply

Your email address will not be published. Required fields are marked *